Myriad Genetics Inc, Salt Lake City, introduces myRisk Hereditary Cancer, a new multigene diagnostic test that will provide increased sensitivity by analyzing 25 genes associated with eight major cancers: breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric, and melanoma.
The test is being released in a phased approach beginning with an early-access, clinical-experience program to a limited number of medical and scientific thought leaders, followed by an expanded-access program later in the year.
The company will present extensive clinical validity data for the test at The Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA) annual meeting in October, and at the San Antonio Breast Cancer Symposium in December.
Myriad says the test represents the next generation of hereditary cancer testing and will give health care providers clear and actionable information to improve patient care, regardless of whether the patient receives a positive or negative test result.
Each test report will include a genetic test result, a clinical risk and health care management tool based on professional society guidelines.
[Source: Myriad Genetics]
